Drug Trial Radar · NCT06834672
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Mar 17, 2025
Primary completion
Dec 28, 2027
Study completion Nov 28, 2029
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multiregional, multicenter, randomized, open-label, phase III study to compare the efficacy, safety, and tolerability of IBI354 monotherapy with investigator's choice of chemotherapy (paclitaxel, gemcitabine, liposomal doxorubicin, or topotecan) in patients with HER2-expressing, platinum-resistant ovarian, primary peritoneal, or fallopian tube cancer. Participants with advanced ovarian, primary peritoneal, fallopian tube cancer who have failed or are intolerant to first-line or more platinum-based chemotherapy will be randomly assigned in a 2:1 ratio to two treatment arms: Experimental Arm: IBI354 monotherapy arm, 12 mg/kg IBI354 on Day 1 of each 3-week cycle; Control Arm: Investigator's choice chemotherapy (paclitaxel, gemcitabine, liposomal doxorubicin, or topotecan)
Conditions
- Ovarian
- Primary Peritoneal
- Fallopian Tube Cancer
Interventions
IBI354Drug
intravenous infusion of 12 mg/kg on Day 1 of each 3-week treatment cycle
paclitaxel/Gemcitabine/Liposomal doxorubicinDrug
paclitaxel:- Usage and dosage: 80 mg/m2 administered as an intravenous infusion on Day 1 of each weekly treatment cycle。 Gemcitabine:Usage and dosage: intravenous infusion at 1000 mg/m2 on Days 1, 8 of each 3-week treatment cycle。 Liposomal doxorubicin:Usage and dosage: intravenous infusion of 40 mg/m2 on Day 1 of each 4-week treatment cycle Topotecan: 1.25 mg/m2, in 3-week cycles (Q3W), on Days 1, 2, 3, 4, and 5 of each cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the Progression-free survival (PFS) of IBI354 monotherapy versus investigator's choice of chemotherapyTime frame: From date of randomization until the occurrence of first documented progression, death from any cause, or the initiation of new anticancer treatment, whichever occurs first (up to approximately 36 months)
- Overall Survival (OS)Time frame: From date of randomization until the date of death from any cause (up to approximately 48 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital of Chongqing University
Chongqing, Chongqing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.